Evidence map›Paper›PMID 28740236›Full record

ArticleScientific reports2017

Reduced expression of the murine HLA-G homolog Qa-2 is associated with malignancy, epithelial-mesenchymal transition and stemness in breast cancer cells.

Istéfani L da Silva, Lucía Montero-Montero, Ester Martín-Villar, Jorge Martin-Pérez, Bruno Sainz, Jaime Renart, Renata Toscano Simões, Émerson Soares Veloso, Cláudia Salviano Teixeira, Mônica C de Oliveira and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Istéfani L da SilvaDepartment of General Pathology, Laboratory of Compared Pathology, Biological Science Institute, Federal University of Minas Gerais, 486, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Lucía Montero-MonteroInstituto de Investigaciones Biomédicas "Alberto Sols", - Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain.
Ester Martín-VillarInstituto de Investigaciones Biomédicas "Alberto Sols", - Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain.
Jorge Martin-PérezInstituto de Investigaciones Biomédicas "Alberto Sols", - Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain.
Bruno SainzInstituto de Investigaciones Biomédicas "Alberto Sols", - Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain.
Jaime RenartInstituto de Investigaciones Biomédicas "Alberto Sols", - Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain.
Renata Toscano SimõesInstitute of Education and Research of Santa Casa of Belo Horizonte, 590, 30150-240, Belo Horizonte, Minas Gerais, Brazil.
Émerson Soares VelosoDepartment of General Pathology, Laboratory of Compared Pathology, Biological Science Institute, Federal University of Minas Gerais, 486, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Cláudia Salviano TeixeiraLaboratory of Pharmacotecniques and Pharmaceutical Technologies, Pharmacy Faculty, Federal University of Minas Gerais, 486, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Mônica C de OliveiraLaboratory of Pharmacotecniques and Pharmaceutical Technologies, Pharmacy Faculty, Federal University of Minas Gerais, 486, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Enio FerreiraDepartment of General Pathology, Laboratory of Compared Pathology, Biological Science Institute, Federal University of Minas Gerais, 486, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
Miguel QuintanillaInstituto de Investigaciones Biomédicas "Alberto Sols", - Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), 28029, Madrid, Spain. mquintanilla@iib.uam.es.
Universidade Federal de Minas Gerais · BRInstituto de Investigaciones Biomédicas Sols-Morreale · ESUniversidad Autónoma de Madrid · ESConsejo Superior de Investigaciones Científicas · ESInsper · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Qa-2 is believed to mediate a protective immune response against cancer; however, little is known about the role of Qa-2 in tumorigenesis. Here, we used 4T1 breast cancer cells to study the involvement of Qa-2 in tumor progression in a syngeneic host. Qa-2 expression was reduced during in vivo tumor growth and in cell lines derived from 4T1-induced tumors. Tumor-derived cells elicited an epithelial-mesenchymal transition associated with upregulation of Zeb1 and Twist1/2 and enhanced tumor initiating and invasive capacities. Furthermore, these cells showed increased stem characteristics, as demonstrated by upregulation of Hes1, Sox2 and Oct3/4, and enrichment of CD44

Indexed as

Epithelial-Mesenchymal TransitionAnimalsApoptosisBreast NeoplasmsCarcinogenesisCell MovementCell ProliferationFemaleHistocompatibility Antigens Class IHumansMiceMice, Inbred BALB CNeoplastic Stem CellsTumor Cells, CulturedXenograft Model Antitumor AssaysHistocompatibility Antigens Class IQ surface antigens

Identifiers

PMID28740236
PMCPMC5524840
OpenAlexW2736734128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.